Navigation Links
Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
Date:2/18/2011

CARY, N.C., Feb. 18, 2011 /PRNewswire/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX) today announced that it will host a conference call at 8:30 AM ET on Thursday, March 3, 2011, to discuss its financial results for the quarter and twelve months ended December 31, 2010. Financial results are expected to be released on Thursday, March 3, 2011, before the open of the U.S. financial markets.

To participate in the live conference call, please dial 866-730-5770 (U.S. callers) or 857-350-1594 (international callers), and provide passcode 99190634. A live webcast of the call will also be available through the Investor Relations section of the Company's website. Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The conference call and the webcast will be archived for 30 days.  The telephone replay of the call will be available at 11:30 AM ET on March 3, 2011 by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 56948345.

About Cornerstone TherapeuticsCornerstone Therapeutics Inc. (Nasdaq CM: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians, key retail pharmacies and hospitals with its specialty sales forces. The Company also has a late-stage pipeline with a recent regulatory submission filing. Key elements of the Company's strategy are to pursue acquisition or licensing transactions to acquire the rights to patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; to implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; to grow product revenue through the Company's specialty sales forces; and to maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements, our ability to enter into strategic licensing, product acquisition, collaboration or co-promotion transactions on favorable terms, if at all, and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 4, 2010 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.ContactsInvestor Relations Contacts: Westwicke Partners, John Woolford, +1-443-213-0506, john.woolford@westwicke.com or Westwicke Partners, Stefan Loren, Ph.D., +1-443-213-0507, sloren@westwicke.com; Media Relations Contact: Fleishman-Hillard, Andrea Moody, +1-919-457-0743, andrea.moody@fleishman.com.
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
2. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
3. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
4. Cornerstone Therapeutics Announces Collaboration with The Cough Company
5. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
6. Cornerstone Therapeutics Announces Management Change
7. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
8. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
9. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
10. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
11. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... Washington, D.C. (PRWEB) , ... June 24, 2016 , ... ... Pro-Am Heroes Golf Classic Tournament held on June 20th at the Woodmont Country ... local charity, Luke’s Wings, an organization dedicated to helping service members that have been ...
Breaking Medicine News(10 mins):